Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06228599 · ClinicalTrials.gov registry record · NA
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence
A NA study of Pancreas Cancer, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06228599: Recruiting NA study of Pancreas Cancer, sponsored by Medical College of Wisconsin.
NCT06228599 is a NA study of Pancreas Cancer that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 40 participants, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06228599, a NA study of Pancreas Cancer, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence post-surgery.
Primary Outcome
The number of subjects exhibiting disease-free survival at six months. Disease-free survival is defined as the time from study therapy initiation until disease recurrence or death from any cause.
Conditions Studied
Interventions
- OTHER Treatment Plan
Study Locations (1)
Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-02-29 |
| Est. Completion | 2026-07-31 |
| Phase | NA |
What NCT06228599 shows while recruiting
NCT06228599 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Pancreas Cancer appearing as the primary indexed condition, and to 1 intervention - of which Treatment Plan is the first listed.
NCT06228599 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06228599 about?
NCT06228599 is a clinical study titled "Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence". This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence post-surgery.
What is the current status of trial NCT06228599?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-02-29. Estimated completion is 2026-07-31.
What conditions does trial NCT06228599 study?
This clinical trial studies the following conditions: Pancreas Cancer.
What interventions are being tested in trial NCT06228599?
The interventions under investigation include: Treatment Plan (OTHER).
Who is sponsoring clinical trial NCT06228599?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06228599 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06228599's enrollment target sits among peer trials
40 34th of 54 higher than 19 of 54 other Pancreas Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreas Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Promoting CT Engagement for Pancreatic Cancer With App
RECRUITING · NA
-
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
RECRUITING · NA
-
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
RECRUITING · NA
-
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
RECRUITING · NA
-
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI